Company · Healthtech & Bio

Batea Oncology

bateaoncology.com ↗ ·Santiago de Compostela ·Seed

Batea Oncology is a Santiago de Compostela-based biotech spun out of the University Hospital and Health Research Institute of Santiago, founded in 2024 to develop new treatments for aggressive, low-survival cancers. Its lead asset, GlioHook, is a Class III implantable medical device placed during glioblastoma surgery that captures residual tumor cells and makes them more sensitive to radiotherapy, with a pilot clinical trial planned for 2026 across three Spanish hospitals.

Founded
2024
Founders
2
News
6
Rounds
1
Investors
4
SectorsBiotech, Oncology, Medical Devices, Healthcare Start-up MapHealthtech & Bio › Medical devices & surgical hardware

Profile updated 30 Jul 2026

Founders

Jorge Barbazán
Co-founder & CSO
Sonia Martínez Arca
Co-founder & CEO

Global models 5

Monteris Medical
United States · www.monteris.com ↗
Develops an implantable laser-ablation device (NeuroBlate) for treating otherwise inoperable brain tumors including glioblastoma, matching Batea's model of a localized surgical device for brain cancer.
$275MComparable
Alpheus Medical
United States · alpheusmedical.com ↗
Develops an ultrasound-activated sonodynamic therapy device specifically for newly diagnosed glioblastoma, targeting the same disease and device-based treatment approach as GlioHook.
$83.4MComparable
CarThera
France · carthera.eu ↗
Develops SonoCloud, an ultrasound-emitting implant placed during glioblastoma surgery to enhance drug delivery to the tumor site, closely mirroring GlioHook's implanted-device-at-surgery model.
$58MComparable
DNAtrix
United States · www.dnatrix.com ↗
Clinical-stage biotech developing an oncolytic virus therapy (DNX-2401) specifically for recurrent glioblastoma, matching Batea's disease focus though via a different treatment modality.
$43MComparable
Novocure
Switzerland · www.novocure.com ↗
Commercializes Optune, a wearable tumor-treating-fields device for glioblastoma that, like GlioHook, targets residual/infiltrative tumor cells post-surgery to improve radiotherapy/treatment outcomes.
$10MComparable

Investors 4

Funding rounds 1

Seed · €750k
Galician biotech Batea Oncology, founded in 2024 with the Hospital Clínico Universitario and the Health Research Institute of Santiago, brou…
2025-09-18

News & media 6

Start typing to search across everything.
↑↓ navigate↵ openesc close